New PhRMA Report: 836 medicines and vaccines in development to treat cancers
Awareness, prevention and treatment options have dramatically improved in recent decades, spelling remarkable progress against one of mankind’s toughest medical challenges.
Awareness, prevention and treatment options have dramatically improved in recent decades, spelling remarkable progress against one of mankind’s toughest medical challenges.
Almost all of us have fought – or know someone who is fighting – the ruthless disease author Siddhartha Mukherjee termed, “the emperor of all maladies.” Today, cancers remain the second-leading cause of death in the United States, and it is estimated that more than 1.6 million new cases of the disease will be diagnosed this year alone. That’s half the population of Alexandria, Egypt – where cancer was first discovered, around 1500 B.C.[1]
Fortunately, awareness, prevention and treatment options have dramatically improved in recent decades, spelling remarkable progress against one of mankind’s toughest medical challenges.
According to a new PhRMA report released today, America’s biopharmaceutical research companies are currently developing 836 medicines and vaccines to treat a broad range of cancers. This is more than have ever been in development globally.
These medicines, all of which are either in clinical trials or awaiting review by the U.S. Food and Drug Administration, include:
These efforts to discover new, more effective treatments represent our best hope for helping cancer patients live longer, healthier lives while continuing to lessen the burden of this disease worldwide.
To celebrate the progress and promise of oncology research and care, PhRMA honored oncology researchers and patient advocates yesterday at the 2015 Research & Hope Awards in Washington, D.C.. Read more about the award recipients at http://www.phrma.org/research-hope-awards.
[1] http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-what-is-cancer
{{cta('13a5edf4-90de-4653-a862-46954152f58b','justifycenter')}}
{{cta('98bf8279-d07a-43f2-a1f6-a0d6f93af01f','justifycenter')}}